Hims & Hers: Buy The Core Engine, Not The Headline

Hims & Hers Health (NYSE:HIMS) stock fell 13% following its Q2 earnings report, as revenue of $544.8 million narrowly missed analyst estimates by approximately $7 million and indicated decelerating growth. Despite this, the company reported robust core business performance excluding GLP-1 products, strong subscriber growth, and nearly doubled adjusted EBITDA year-over-year. Hims & Hers maintained its full-year 2025 guidance, signaling confidence in its ability to absorb volatility and expand into new categories despite GLP-1 headwinds.

Analysis

The market's reaction to Hims & Hers Health's second-quarter results, which precipitated a 13% stock decline, appears to be a response to a narrow revenue miss of approximately $7 million against analyst estimates. Despite this, the company reported substantial top-line growth of 73% year-over-year, reaching $544.8 million. The underlying operational metrics signal strength, with the core business ex-GLP-1 products described as robust, supported by strong subscriber growth and improving profitability. Notably, adjusted EBITDA nearly doubled year-over-year, and a higher average revenue per subscriber is successfully offsetting margin pressures from product mix shifts. Management's decision to maintain full-year 2025 guidance, despite headwinds in the GLP-1 market, signals confidence in its operational execution and ability to expand into new categories. The situation presents a dichotomy between a negative market sentiment driven by decelerating growth and a miss on estimates, versus strong fundamental performance and a confident management outlook, framing the stock as a high-risk, high-reward proposition within the telehealth sector.

Key Decisions for Investors

• Investors could interpret the 13% stock decline as a potential buying opportunity, viewing the market's reaction to the slight revenue miss as disproportionate to the strong 73% year-over-year growth and doubling of adjusted EBITDA.
• Focus on the performance of the core business, particularly subscriber growth and average revenue per subscriber, as these metrics appear strong and are insulated from the volatility of the GLP-1 segment.
• Given the stock is characterized as a high-risk/high-reward play, it is prudent to manage position size carefully to mitigate against potential volatility and broader telehealth sector risks.
• Closely monitor the company's ability to meet its maintained full-year 2025 guidance, as its achievement is a critical component of the bull thesis and a key indicator of management's execution capabilities.